
WuXi Biologics (Cayman) Inc.
WXIBF
Updated: 24/09/2026, 03:39:51
WuXi Biologics (Cayman) Inc. provides extensive global services, spanning the entire biopharmaceutical process from drug discovery to advanced development and manufacturing, catering to clients in China, North America, Europe, and other international markets. The company also offers expert consultation in biopharmaceutical technology, facilitates international sales contracting, develops and performs advanced testing services, and manages sales and marketing initiatives. Furthermore, it provides clinical and manufacturing support for biologics, manufactures and distributes medical products, serves as a contract development and manufacturing organization (CDMO) for vaccines, and functions as a material supplier. WuXi Biologics maintains significant strategic collaborations with partners such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc. The organization, founded in 2014, is headquartered in Wuxi, China.
No summaries found.
- Share price
- $6.01
- Market cap
- $24.90B
- Exchange
- OTC
- Currency
- USD
- CEO
- Zhisheng Chen
- Employees
- 13,252
- IPO date
- 30/01/2018
- Beta
- 0.598
- Last dividend
- $0.00
- Day range
- $6.01 – $6.45
- 52-week range
- $3.90 – $6.45
- 1-day performance
- 0.00%
- 1-year performance
- 54.10%
- Current drawdown (1Y)
- -6.82%
- CIK
- N/A
- CUSIP
- G97008117
- ISIN
- KYG970081173
- Created
- 07/12/2025, 15:08:48
- Last update
- 24/09/2026, 03:39:51
Track WuXi Biologics (Cayman) Inc. with an AI analyst
See which prediction-market events move WXIBF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.